Feng Xu
North Sichuan Medical University
ORCID: 0000-0002-1172-3859Also affiliated with Nanjing General Hospital of Nanjing Military Command, University Hospital, Newark, China National Pharmaceutical Group Corporation (China), Radiation Oncology Institute, Huainan Normal University, Beijing YouAn Hospital, Nanchong Central Hospital, Children's Hospital of Chongqing Medical University, Nanjing Medical University, Xi'an Jiaotong University, Chongqing Medical University, Nanjing University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 1 paper. Top paper: “Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results”.
Thomas E. Stinchcombe, Mrinal M. Gounder, Gregory M. Coté, Glenn J. Hanna, Bradley Sumrall +16 more